Bavarian begins phase III trial of RSV vaccine in older adults

The first person has received Bavarian Nordic’s vaccine candidate against respiratory syncytial virus in a late-stage global study.
Photo: Philip Davali/Ekstra Bladet, Philip Davali
Photo: Philip Davali/Ekstra Bladet, Philip Davali
by marketwire, translated by daniel pedersen

Bavarian Nordic has administered the first shot of its RSV vaccine in a phase III trial with older adults, and the global study is therefore now underway, the company has announced in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading